68Ga与Al18F标记PSMA/FAP双特异性示踪剂的前临床评价及首次人体研究
本研究开发了基于联苯骨架的PSMA/FAP双特异性示踪剂,在前临床模型中评估其亲和力与PET显像效果,并在两例前列腺癌患者中初步比较[18F]AlF-NOTA-PSFA-1与[68Ga]Ga-PSMA-11的显像表现。
要点
- 双特异性示踪剂对PSMA和FAP均具高亲和力,前临床模型中肿瘤摄取高且滞留良好。
- [18F]AlF-NOTA-PSFA-1在22Rv1和U87MG模型中SUVmax分别为4.64和7.23。
- 首次人体中[18F]AlF-NOTA-PSFA-1较[68Ga]Ga-PSMA-11病灶摄取更高、本底更低、图像质量更优。
核心结论
- 联苯骨架PSMA/FAP双特异性示踪剂在前临床模型中实现高肿瘤亲和力、长滞留及明显降低的肾脏摄取。
- [18F]AlF-NOTA-PSFA-1为最有前景的候选,前临床与首次人体评价中显像性能优于[68Ga]Ga-PSMA-11。
研究设计与样本
- 前临床研究:评估前体及非放射性标准品的PSMA/FAP结合亲和力,并在22Rv1(PSMA阳性)和U87MG(FAP阳性)荷瘤模型中进行PET/CT显像。
- 首次人体研究:在两例前列腺癌患者中评估[18F]AlF-NOTA-PSFA-1,并与[68Ga]Ga-PSMA-11直接比较;临床试验注册号NCT06690970。
主要发现
- 所有前体及非放射性标准品对PSMA(Ki=0.13-4.86 nM)和FAP(Ki=0.012-0.40 nM)均显示高亲和力。
- [18F]AlF-NOTA-PSFA-1在22Rv1模型SUVmax=4.64、U87MG模型SUVmax=7.23,为所评估示踪剂中肿瘤摄取最高,且随时间保持良好肿瘤滞留。
- 与[68Ga]Ga-PSMA-11相比,[18F]AlF-NOTA-PSFA-1在转移性前列腺癌患者中病灶摄取更高、脱靶器官本底累积更低、图像质量改善。
关键数值与推荐
- PSMA结合亲和力Ki范围为0.13-4.86 nM。
- FAP结合亲和力Ki范围为0.012-0.40 nM。
- [18F]AlF-NOTA-PSFA-1在22Rv1模型SUVmax=4.64,在U87MG模型SUVmax=7.23。
临床怎么用
- PSMA/FAP双靶向策略可能互补PSMA表达下降时的显像不足,[18F]AlF-NOTA-PSFA-1值得进一步临床验证。
- 首次人体数据提示[18F]AlF-NOTA-PSFA-1在前列腺癌病灶探测和图像质量方面可能优于[68Ga]Ga-PSMA-11。
局限性
- 首次人体评价仅纳入两例前列腺癌患者,样本量有限。
- 前临床数据来自22Rv1和U87MG荷瘤小鼠模型,向临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA) expression may decrease during the progression of prostate cancer (PCa), compromising the efficacy of PSMA-targeted imaging. Fibroblast activation protein (FAP), a key component of the tumor microenvironment, offers a complementary target. This study aimed to develop and evaluate PSMA/FAP bispecific tracers with a biphenyl scaffold for improved PET detection outcomes of PCa. METHODS: The binding affinities of precursors and their corresponding non-radioactive standards were assessed using recombinant PSMA and FAP proteins. PET/CT imaging was performed in 22Rv1 (PSMA-positive) and U87MG (FAP-positive) xenograft models. Clinical evaluation of [18F]AlF-NOTA-PSFA-1 was conducted in two PCa patients, directly compared with [68Ga]Ga-PSMA-11. RESULTS: All precursors and their corresponding non-radioactive standards exhibited high affinity for both PSMA (Ki = 0.13-4.86 nM) and FAP (Ki = 0.012-0.40 nM). Among them, [18F]AlF-NOTA-PSFA-1, demonstrated the highest tumor uptake in both 22RV1 (SUVmax = 4.64) and U87MG (SUVmax = 7.23) models, along with favorable tumor retention over time. Compared to [68Ga]Ga-PSMA-11, [18F]AlF-NOTA-PSFA-1 showed higher lesion uptake, reduced background accumulation in off-target organs, and improved imaging quality in metastatic PCa patient. CONCLUSIONS: The biphenyl-based bispecific tracers developed in this study achieved high tumor affinity, prolonged retention, and notably reduced renal uptake in mouse models. [18F]AlF-NOTA-PSFA-1 emerged as the most promising candidate, demonstrating superior imaging performance over [68Ga]Ga-PSMA-11 in both preclinical and first-in-human evaluation. TRIAL REGISTRATION: Clinical trial registry NCT06690970, Registered 14 Nov 2024.
引用
- Wang X, Wang M, Chen Y, et al. Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA/FAP bispecific tracers for prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2025. PMID: 41120594. doi:10.1007/s00259-025-07591-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。